The Impact of Methylenetetrahydrofolate Reductase Gene Polymorphisms on Iraqi Patients with Diabetic Nephropathy

Authors

  • Safa A. Ali Clinical Biochemistry, Department of Biochemistry, College of medicine, university of Baghdad, Iraq Author
  • Zainab A. Razak ALsharifi Clinical Biochemistry, Department of Biochemistry, College of medicine, university of Baghdad, Iraq 3 Author
  • Ali Abdul Majid Allawi Department of nephrologcal, Baghdad Teaching Hospital, Baghdad, Iraq Author

DOI:

https://doi.org/10.61841/j3z39h37

Keywords:

reductase, nephropathy, polymorphisms

Abstract

Diabetic nephropathy is a major cause of end-stage renal disease. Micro albuminuria is a term to describe a moderate increase in the level of urine albumin. It occurs when the kidney leaks mall amounts of albumin into the urine. The aim of this study was to investigate the influence of the C677T and A1298C polymorphisms of methylene tetrahydrofolate on the progression of chronic kidney disease in diabetic nephropathy of Iraqi patients to delay the deterioration in renal function. A hospital-based case-control study was performed. A total of 60 patients with diabetic nephropathy age (24-87) and 60 controls age (16-68) selected from nephrology center in Bagdad Teaching Hospital /Medical City from December 2017 until the end of August 2018, shows mean differences of study markers including (FBS, Blood urea, Serum creatinine and MTHFR) according to study group (micro albuminuria and control group). There were significant differences between means of all markers according to study group. in result conclusion Urinary biomarkers were significantly elevated in normoalbuminuric type 2 diabetic patients compared with nondiabetic control subjects and could be used as markers of diabetic nephropathy (DN) at a very early stage even before the development of micro albuminuria. 

Downloads

Download data is not yet available.

References

1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J (2010). American Diabetes Association. Diagnosis and Classification of diabetes mellitus. Diabetes Care.(2)5-8

2. Rother KI (April 2007). "Diabetes treatment – bridging the divide". The New England Journal of Medicine. 356 (15): 1499–501

3. Shoback DG, Gardner D, eds. (2011). "Chapter 17". Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-162243-1.

4. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, Orchard TJ, Aiello LP, King GL (2007). Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care30: 1995-1997

5. Smeltzer,S.; Bare, B.; Hinkle, J. and Cheever, K (2010) Textbook of Medical-Surgical Nursing, 11th ed., Philadelphia; Lippincott- Williams and Wilkins, USA, PP.1325-132.

6. Weinheim Wiley(2010). Urea", Ullmann's Encyclopedia of Industrial Chemistry, 10.1002/14356007.a27_333.

7. Baumgarten M(2011). Chronic Kidney Disease: Detection and Evaluation. Am Fam Physician. 15;84(10):1138-1148

8. Abid O, Sun Q, Sugimoto K, Mercan D, Vincent JL (2001). "Predictive value of microalbuminuria in medical ICU patients: results of a pilot study". Chest. 120 (6): 1984–8

9. Xiong X, Lin XK, Xiao X, Qin DP, Zhou DY, Hu JG, Liu Y, Zhong XS (2016). Association between MTHFR C677T polymorphism and diabetic nephropathy in the Chinese population: An updated metaanalysis and review ;21(1):5-12.

10. Ramanathan G, Harichandana B, Kannan S, Elumalai R, Sfd P (2019). Association between end-stage diabetic nephropathy and MTHFR (C677T and A1298C) gene polymorphisms, 24(2):155-159.

Downloads

Published

30.04.2020

Issue

Vol. 24 No. 2 (2020): 24 (2) 2020

Section

Articles

License

Copyright (c) 2020 AUTHOR

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

A. Ali, S., A. Razak ALsharifi, Z., & Abdul Majid Allawi, A. (2020). The Impact of Methylenetetrahydrofolate Reductase Gene Polymorphisms on Iraqi Patients with Diabetic Nephropathy. International Journal of Psychosocial Rehabilitation, 24(2), 191-194. https://doi.org/10.61841/j3z39h37